# Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

> **NCT02198664** · PHASE2 · COMPLETED · sponsor: **Aimmune Therapeutics, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **BIOLOGICAL:** AR101 - Peanut protein capsule

## Key facts

- **NCT ID:** NCT02198664
- **Lead sponsor:** Aimmune Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-27
- **Primary completion:** 2018-01-04
- **Final completion:** 2018-01-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02198664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02198664, "Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT02198664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*